BioWorld

Feb. 25, 2003

VaxGen's AIDS Vaccine Comes Up Short; Blacks, Asians Show Benefit

VaxGen Inc. did not receive the results it and so many others hoped for after releasing Phase III trial data for its experimental AIDS vaccine, resulting in an investment backlash against the company's stock. (BioWorld Today) Read More

Trimeris, Roche Implement Program In Europe, Set Price

Monocyte Cells, Easily Accessible To Draw From Blood, Can Double For Dicey Embryonic Stem Cells

Peregrine Gets FDA OK For Cotara Phase III, Awaits Partner

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...